PAHO panel weighs stripping U.S. and Mexico of measles elimination status

A Pan American Health Organization advisory commission is meeting this week to decide whether the United States and Mexico have lost their measles elimination status. The panel is examining whether the same measles virus has been spreading continuously within North America since 2024. If it finds sustained transmission lasting one year or more, PAHO Director Jarbas Barbosa can revoke the designation. Canada already lost its measles-free status last year after a similar review. PAHO officials said an announcement is being scheduled for next week.

The evidence is genetic. Commission members are checking whether outbreak viruses share the same lineage long enough to meet PAHO's definition of endemic circulation, rather than repeated imported cases. The United States had been considered measles eliminated for about 30 years, but outbreaks over the past two years have produced thousands of illnesses and about a dozen deaths. CDC Director Erica Schwartz said losing the designation would not change the agency's outbreak response, while many experts argue it requires a stronger vaccination campaign.

The decision sits where public health and politics meet. PAHO's measles elimination program treats continuous domestic transmission as a failure to maintain high vaccination coverage and rapid outbreak control. In the United States, Health Secretary Robert F. Kennedy Jr. has pushed to reduce the childhood vaccination schedule and reshape vaccine advisory bodies, moves that medical groups say could weaken routine immunization. The panel's genetic method is narrow, but its political meaning is broad: a regional certification once seen as a shared U.S.-Mexico achievement is now in question.

The stakes are immediate for children, travelers and communities with low vaccine coverage, because measles spreads easily and can cause pneumonia, brain inflammation and death. A loss of elimination status signals that routine prevention has broken down, even if it does not by itself change clinical care. This is a public-health classification, not a trial: genomic and surveillance data can show sustained circulation but cannot by themselves measure vaccine effectiveness or prove policy causes. Next needs published sequences, coverage data and transparent outbreak investigations.